Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0363420160300020001
Journal of Korean Oriental Pediatrics
2016 Volume.30 No. 2 p.1 ~ p.9
The Anti-inflammatory Effects of Hataedock Taken Douchi Extracts on Atopic Dermatitis-like Skin Lesion of NC/Nga Mous
Aum Sun-Ho

Ahn Sang-Hyun
Park Sun-Young
Cheon Jin-Hong
Kim Ki-Bong
Abstract
Objectives: Hataedock is a Korean herbal medical oral treatment that removes fetal toxic heat and meconium from new born babies. The purpose of this study is to evaluate whether Hataedock treatment of Duchi extracts has anti-inflammation
effects on AD (Atopic Dermatitis)-induced NC/Nga mice.

Methods: After Hataedock treatment of Duchi extracts on days 0, 3-week-old NC/Nga mice were sensitized on days 28,
35, 42 by exposure of DNFB (dinitrochlorobenzene) and were induced to have AD. Immunohistochemistry of NF-¥êB p65, iNOS, COX-2 and TUNEL assay of apoptotic body was used to identify changes of skin damages and anti-inflammation effects.

Results: The alleviate effect of the skin damage and angiogenesis was observed in DT group. The damage of stratum
corneum, hyperplasia, edema, infiltration of lymphocytes and distribution of capillary were decreased in DT group.
Also, the study results suggested that Hataedock treatment of Duchi extracts in DT group remarkably downregulated
levels of NF- ¥êB p65 by 70% (p < 0.001), as well as COX-2 by 51%, iNOS by 62% (p < 0.001). Additionally, Hataedock treatment of Duchi extracts in DT group up-regulated apoptosis of inflammatory cells by 68% in atopic dermatitis-like skin lesion.

Conclusions: From the study results, we observed that Hataedock treatment of Duchi extracts alleviates AD through
diminishing various inflammatory cytokines in the skin lesions, which are involved in the initial steps of AD development. It is anticipated to have potential applications for prevention and treatment of atopic dermatitis.
KEYWORD
Hataedock, Duchi, Atopic dermatitis, NF- ¥êB, iNOS, Apoptosis
FullTexts / Linksout information
 
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed